Why Sharps Technology (STSS) Stock Is Skyrocketing

Sharps Technology Inc STSS shares are trading higher by 39.8% to $0.63 during Thursday’s session after the company signed a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals.

The company says the deal complements Sharps Technology’s acquisition of InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be North America’s only dedicated COC prefillable syringe manufacturing plant, featuring advanced production capabilities.

Product delivery is set to start in late second-quarter 2025, with expected revenue of about $37 million in the first year.

See Also: US Q1 Economic Growth Downwardly Revised To 1.3%: Consumer Spending Falters

How To Buy STSS Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Sharps Technology’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, STSS has a 52-week high of $1.05 and a 52-week low of $0.17.